| A537 |
Fresolimumab
Featured
|
Fresolimumab (GC1008) is a human monoclonal antibody against TGF-β that neutralizes all mammalian active subtypes of TGF-β. The binding affinity of Fresolimumab to TGF-β2 is 1.8 nM. Fresolimumab radiolabeled with 89Zr can be used for PET analysis of TGF-β expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease. |
|
| A538 |
Bintrafusp alfa
Featured
|
Bintrafusp alfa (M 7824) is a first-in-class bifunctional fusion protein composed of the extracellular domain of TGF-βRII fused to a human IgG1 mAb blocking programmed cell death ligand. Bintrafusp alfa can be used for the research of cancer. |
|
| A539 |
Nisevokitug
Featured
|
Nisevokitug (NIS-793) is a human, IgG2λ antibody targeting TGF-β (TGFB1/TGFB2). Nisevokitug is expressed by CHO-K1 cells. |
|
| A540 |
Genzyme patent anti-TGF-β
Featured
|
|
|
| A541 |
Zampilimab
Featured
|
Zampilimab (UCB-7858) is a monoclonal antibody against transglutaminase 2 (TG2). Zampilimab has potential application in renal transplant. |
|
| A542 |
Regeneron patent anti-TIE-2
Featured
|
|
|
| A543 |
Tiragolumab
Featured
|
Tiragolumab is an immune checkpoint inhibitor binding to T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab, alone or in combination with the PD-L1 inhibitor Atezolizumab (HY-P9904), may be effective against multiple solid malignancies-most notably non-small cell lung cancer (NSCLC). |
|
| A544 |
Vibostolimab
Featured
|
Vibostolimab is an anti-TIGIT (T cell immunoglobulin and ITIM domain) monoclonal antibody. Vibostolimab shows antitumor activity, and can be used in non-small cell lung cancer (NSCLC) and melanoma research. |
|
| A545 |
Ociperlimab
Featured
|
Ociperlimab is a humanized IgG1 anti-TIGIT antibody. Ociperlimab binds to the extracellular domain of human TIGIT with high affinity (KD = 0.135 nM). Ociperlimab blocks the interaction between TIGIT and its ligands PVR or PVR-L2. Ociperlimab can be used in research of cancer. |
|
| DC67103 |
Nerandomilast dihydrate
Featured
|
Nerandomilast (BI 1015550) dihydrate is an orally active inhibitor of PDE4B with an IC50 value of 7.2 nM. Nerandomilast (dihydrate) has good safety and potential applications in inflammation, allergic diseases, pulmonary fibrosis, and chronic obstructive pulmonary disease (COPD). |
|
| A546 |
Etigilimab
Featured
|
Etigilimab (OMP-313M32), a humanized IgG1 monoclonal antibody, blocks TIGIT interaction with PVR (CD155; poliovirus receptor) and inhibits downstream signalling with target cell killing. |
|
| A547 |
Domvanalimab
Featured
|
Domvanalimab (AB154) is an anti-TIGIT humanized monoclonal antibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used in research of cancer. |
|
| A548 |
Cobolimab
Featured
|
Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC). |
|
| A549 |
Sabatolimab
Featured
|
Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells. |
|
| A550 |
Tomaralimab
Featured
|
Tomaralimab (OPN-305) is a humanised anti-TLR2 IgG4 monoclonal antibody. Tomaralimab has the potential for the research of Myelodysplastic Syndromes (MDS). |
|
| A551 |
Anti-TLR3/CD283 Antibody (CNTO5429)
Featured
|
|
|
| A552 |
U.Tokyo patent anti-TLR7
Featured
|
|
|
| A553 |
Beth Israel Patent Anti-TM4SF1
Featured
|
|
|
| A554 |
Bluefin patent anti-TMEFF1
Featured
|
|
|
| A555 |
Janssen patent anti-TMEFF2
Featured
|
|
|
| A556 |
Regeneron patent anti-TMPRSS2
Featured
|
|
|
| A557 |
Mapatumumab
Featured
|
Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). Mapatumumab can be used for the research of cancer. |
|
| A558 |
Lexatumumab
Featured
|
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research. |
|
| A559 |
Drozitumab
Featured
|
Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma. |
|
| A560 |
Benufutamab
Featured
|
Benufutamab (GEN1029) is a death receptor 5 (DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects. |
|
| A561 |
Conatumumab
Featured
|
Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers. . |
|
| A562 |
Tilogotamab
Featured
|
Tilogotamab (GEN-1029) is an agonistic hexamer formation-enhanced mixture of two antibodies that target two separate epitopes on death receptor type 5 (DR5). Tilogotamab specifically binds to and activates DR5. Tilogotamab can be used for the research of multiple myeloma (MM). |
|
| A563 |
Enavatuzumab
Featured
|
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo . |
|
| A564 |
Ianalumab
Featured
|
Ianalumab (VAY-736) is a human, decarboxylated antibody against BAFF-R. Ianalumab can block the interaction between BAFF and BAFF-R and antagonize the apoptosis protection mediated by BAFF. Ianalumab exerts antibody-dependent cytotoxic (ADCC), depending on effector cell activation mediated by immune receptor tyrosine activation motif (ITAM). |
|
| DC67104 |
DCP-LA(FR 236924)
Featured
|
DCP-LA (FR236924), a linoleic acid derivative, selectively and directly activates PKCε. DCP-LA activates Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) and inhibits protein phosphatase-1 (PP-1) to stimulate AMPA receptor exocytosis. DCP-LA inhibits activation of caspase-3/-9 and protects neurons at least in part from oxidative stress-induced apoptosis. |
|
